BroadOak Capital Partners | Activity | F4BroadOak Capital Partners Activity
Every public signal F4 has attached to this firm, with sources and cross-entity links.
News
BroadOak Partners was exclusive financial advisor to Worldwide Clinical Trials on the sale.
Worldwide Clinical Trials sells Early Phase Services business to Fortrea
Lanterne Dx completed its merger with BroadOak portfolio company Flagship Biosciences.
Exit
Portfolio company Biocare Medical was acquired by Agilent Technologies.
Biocare Medical
Milestone
InSphero acquired PhenoVista Biosciences, a merger of two BroadOak portfolio companies.
Insphero
Investment
Quartzy announced $23M of financing from Avenue Capital Group and BroadOak.
Quartzy
Investment
Supported Harvard Bioscience with a $40M growth financing package and debt refinancing.
Harvard Bioscience
New Fund
Added more than $200 million of permanent capital to its investment platform.
$200M+ permanent capital added to investment platform
Investment
Codis raised growth capital to expand commercial manufacturing, with BroadOak supporting.
Codis
News
BroadOak advised the Enzo Biochem board on the take-private by Battery Ventures.
Battery Ventures take-private of Enzo Biochem
Investment
Pluristyx completed an investment round to expand inventory and commercial operations.
Pluristyx
Milestone
Particle Dynamics acquired EuroAPI UK, a commercial spray drying facility.
Particle Dynamics
Exit
Halo Labs was acquired by Waters Corporation.
Halo Labs
Investment
Invested in PAK BioSolutions' $12M Series A.
PAK BioSolutions
Investment
Invested in Indee Labs from the BroadOak BioTools Venture Fund.
Indee Labs